Get the Stockscreener App
2.05
1.91%
-0.04
After Hours:
2.05
Gri Bio Inc stock is traded at $2.05, with a volume of 53,336.
It is down -1.91% in the last 24 hours and up +4.59% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.09
Open:
$2.07
24h Volume:
53,336
Relative Volume:
0.17
Market Cap:
$4.48M
Revenue:
-
Net Income/Loss:
$-10.91M
P/E Ratio:
-0.0258
EPS:
-79.5513
Net Cash Flow:
$-12.14M
1W Performance:
+6.22%
1M Performance:
+4.59%
6M Performance:
-13.50%
1Y Performance:
-96.21%
1-Day Range:
$1.9501
$2.08
1-Week Range:
$1.85
$2.19
52-Week Range:
$1.36
$64.12
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
2.05 | 4.48M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio Company Profile & Introduction - Moomoo
GRI Bio, Inc.Common Stock (NQ: GRI - The Chronicle-Journal
What date does GRI Bio, Inc.'s (GRI) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
GRI Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a IPF Biomarker Data - TipRanks
Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621 - Investing.com Nigeria
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
GRI Bio Reports Phase 2a Data Showing Repair Phenotype and FVC Improvement with GRI-0621 in Idiopathic Pulmonary Fibrosis - quiverquant.com
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - Stock Titan
GRI Q2 2026 Earnings: Narrower-Than-Expected Loss Overshadowed by 30.6% Stock SlideProduct Revenue Analysis - careplusvn.com
symbol__ Stock Quote Price and Forecast - CNN
What Put GRI Bio (NASDAQ:GRI) on the Nasdaq Composite Radar? - kalkinemedia.com
GRI Bio Surges As Phase 2a IPF Drug Data Nears - StocksToTrade
GRI Bio Jumps As Positive IPF Drug Data Nears ERS Stage - timothysykes.com
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF - HCPLive
GRI Bio Surges As Phase 2a IPF Data Near ERS Reveal - timothysykes.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
GRI|GRI Bio Inc|Price:2.880|Chg%:+0.590 - TradingKey
GRI Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.71% Share GainEarnings Expansion Phase - dars.gov.et
GRI Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.91 Per Share Beats EstimatesLow Estimate Range - dars.gov.et
GRI Bio will present data on its once-daily oral drug in Barcelona this September - Stock Titan
GRI Bio Featured in "Why Now" On-Demand Video Webcast - Yahoo Finance
OSRH Stock Price and Chart — OTC:OSRH - tradingview.com
Fortis (FTS) Financial Results: The Available Earnings Metric Delivers a Beat at the Close; Price Move: Shares Move 0.77% Higher in the Latest ReadingConsensus Beat Rate - vinanet.vn
CHGA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital - Moomoo
GRI (GRI) EPS and Revenue: Reported EPS Misses Expectations in the Latest Reading; Market Move: The Stock Loses 3.47% in the Current UpdateEarnings Forecast Report - vinanet.vn
GRI Bio Inc. (GRI) Climbs 3.6% to $1.73 as Buyers Defend Key SupportWyckoff Accumulation - vinanet.vn
GRI (GRI) Report Card: The Available Earnings Metric Delivers a Miss for This Review; Share Response: Shares Finish 1.73% Higher in the Latest SessionROIC Trend Report - careplusvn.com
GRI Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss of $1.61 Per Share, Yet Stock Closes Up 3.59 - vinanet.vn
GRI Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Shares Slide 5.65%Earnings Forecast Report - vinanet.vn
GRI Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary - TradingView
Form 10-Q GRI Bio, Inc. For: Jun 30 - StreetInsider
GRI Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
GRI Q2'26 Earnings: revenue estimate is 0 USD - TradingView
GRI Bio Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
GRI Bio (GRI) Jumps 15.65% to $1.70 — Breakout Above $1.78 Could Extend RallyDealer Positioning - careplusvn.com
GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates - kalkine.ca
GRI Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage BurnBuyback Announcement Report - vinanet.vn
GRI Bio Inc (GRI) Cash Flow - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
GRI Bio Inc (GRI) Income Statement - TradingKey
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):